Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GlaxoSmithKline plc
  6. News
  7. Summary
    GSK   GB0009252882


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sanofi bets on mRNA vaccines beyond COVID in $3.2 billion Translate Bio deal

08/03/2021 | 09:29am EDT
FILE PHOTO: Sanofi logo is seen in Paris

PARIS (Reuters) - Sanofi has agreed to buy U.S. biotech company Translate Bio in a $3.2 billion deal, as it bets on next-generation mRNA vaccine technology beyond the COVID-19 pandemic, confirming a Reuters exclusive report.

The French pharmaceuticals firm said it would acquire all outstanding shares of Translate Bio for $38.00 per share in cash, representing a total equity value of about $3.2 billion.

The boards of both companies have approved the deal, and the chief executive of Translate Bio and the U.S. company's largest shareholder have backed it, Sanofi and Translate Bio said in a joint statement.

Sanofi shares were little changed at 86.73 euros as of 1125 GMT.

"Translate Bio adds an mRNA technology platform and strong capabilities to our research, further advancing our ability to explore the promise of this technology to develop both best-in-class vaccines and therapeutics," Sanofi CEO Paul Hudson said.

Sanofi's offer of $38 represented a 30.4% premium on the New York-listed company's Aug. 2 closing share price.

In pre-market U.S. trading on Tuesday, Translate Bio's stock was up almost 30% in line with the Sanofi offer. In extended trading late on Monday after the Reuters report and before the financial terms had been announced, they had soared more than 70% to above $50.


Sanofi's bid for Translate Bio marks the latest interest by a large pharmaceutical company in mRNA technology, following its proven success in COVID-19 vaccines developed by Pfizer/BioNTech and Moderna.

Analysts said the price made strategic sense, a long-term wager on mRNA vaccine technology beyond COVID-19 by one of the world's top flu vaccine makers.

"Since COVID, mRNA vaccines have made a big impact on the future of vaccine R&D and the most obvious target for next-generation mRNA vaccines is influenza," Liberum wrote in a briefing note.

The messenger RNA (ribonucleic acid) approach, an area of Translate Bio expertise, instructs human cells to make specific proteins that produce an immune response to a given disease. Sanofi and Translate Bio joined forces last year to develop an mRNA-based COVID-19 vaccine. They expect interim results of their Phase I/II clinical trial in the third quarter.

The two companies are also looking at mRNA vaccines for several infectious diseases and in June started a Phase I trial evaluating a possible mRNA-based vaccine against seasonal flu.

Rival Moderna launched a Phase I/II trial into a possible mRNA flu shot in July.


Sanofi expects to complete the acquisition in the third quarter of 2021.

Translate Bio's chief executive and its largest shareholder, Baupost Group, signed binding commitments to support the deal. Their shares combined with those already held by Sanofi represent about 30% of Translate Bio's total shares outstanding. Sanofi's interest comes after a tough year for the French drugmaker after falling behind rivals in the COVID-19 vaccine race, a major blow to CEO Hudson who joined the company almost two years ago. Sanofi warned last year its traditional, protein-based COVID-19 jab developed with GlaxoSmithKline showed an insufficient immune response in older people, delaying its launch until toward the end of 2021. Hudson has also been under increasing pressure to reduce the company's dependence on its star eczema treatment Dupixent to boost earnings.

Earlier this year, Sanofi agreed to fill and pack millions of doses of shots made by Pfizer/BioNTech, Johnson & Johnson and Moderna. Translate Bio, set up in 2016, has not launched any drugs on the market but its clinical-stage pulmonary product using its mRNA platform is being tested as an inhaled treatment for cystic fibrosis in a Phase I/II clinical trial.

(Reporting by Matthias Blamont, Sudip Kar-Gupta and Richard Lough in Paris; editing by Sonali Paul, Louise Heavens and Jason Neely)

By Matthias Blamont and Sudip Kar-Gupta

ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
GLAXOSMITHKLINE PLC -1.05% 1415.8 Delayed Quote.5.37%
MODERNA, INC. 3.15% 454.6 Delayed Quote.335.15%
SANOFI 0.16% 82.86 Real-time Quote.5.29%
TRANSLATE BIO, INC. -0.13% 37.36 End-of-day quote.0.00%
02:10aGLAXOSMITHKLINE : Federal Circuit Vacates Judgment, Reinstates Jury's Verdict Of Induced I..
09/23GLOBAL MARKETS LIVE : Valneva,Boeing, Facebook, Kubota, Otis...
09/23Activist Bluebell Capital Takes Small Stake in GSK to Push for Board Change -FT
09/23GLAXOSMITHKLINE : Survey Shows More People In Favor Of Vaccinations After COVID-19
09/22GLAXOSMITHKLINE : CEO Faces Additional Pressure as Bluebell Joins Elliott in Demanding Man..
09/22GLAXOSMITHKLINE : Activist investor Bluebell takes stake in GSK to challenge chief exec
09/22Bluebell Capital Takes Stake in GlaxoSmithKline to Shake-up the Company’s Leadership
09/22GLAXOSMITHKLINE : Bluebell Capital Says Believes GSK Should Address Leadership For ôNew GS..
09/22Bluebell capital says believes gsk's emma walmsley would have been a very credible cand..
09/22Activist investor Bluebell takes stake in GSK
More news
Analyst Recommendations on GLAXOSMITHKLINE PLC
More recommendations
Sales 2021 33 307 M 45 715 M 45 715 M
Net income 2021 3 857 M 5 294 M 5 294 M
Net Debt 2021 20 885 M 28 667 M 28 667 M
P/E ratio 2021 18,5x
Yield 2021 5,66%
Capitalization 70 770 M 97 195 M 97 136 M
EV / Sales 2021 2,75x
EV / Sales 2022 2,57x
Nbr of Employees 94 066
Free-Float 92,2%
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 1 414,00 GBX
Average target price 1 604,94 GBX
Spread / Average Target 13,5%
EPS Revisions
Managers and Directors
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Karenann K. Terrell Chief Digital & Technology Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON4.75%431 543
ROCHE HOLDING AG10.05%322 644
PFIZER, INC.19.40%246 414
NOVO NORDISK A/S50.62%232 291